BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28680277)

  • 1. Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.
    Rushton M; Johnson C; Dent S
    Curr Oncol; 2017 Jun; 24(3):176-180. PubMed ID: 28680277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
    Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
    Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study.
    Moey MYY; Liles DK; Carabello BA
    Cardiooncology; 2019; 5():9. PubMed ID: 32154015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy.
    Yao RJR; Gibson J; Simmons C; Davis MK
    Cardiooncology; 2021 Mar; 7(1):12. PubMed ID: 33766148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.
    Leung HW; Chan AL
    Expert Opin Drug Saf; 2015; 14(11):1661-71. PubMed ID: 26461271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population.
    Law W; Johnson C; Rushton M; Dent S
    Curr Oncol; 2017 Oct; 24(5):e348-e353. PubMed ID: 29089804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study.
    Gunaldi M; Duman BB; Afsar CU; Paydas S; Erkisi M; Kara IO; Sahin B
    J Oncol Pharm Pract; 2016 Apr; 22(2):242-7. PubMed ID: 25567518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity of novel HER2-targeted therapies.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
    J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer.
    Nowsheen S; Viscuse PV; O'Sullivan CC; Sandhu NP; Haddad TC; Blaes A; Klemp J; Nhola L; Herrmann J; Ruddy KJ
    Curr Breast Cancer Rep; 2017 Sep; 9(3):173-182. PubMed ID: 29225726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada.
    Rushton M; Kappel C; Lima I; Tuna M; Pritchard K; Hawken S; Dent S
    Front Cardiovasc Med; 2022; 9():850674. PubMed ID: 35665245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
    Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
    Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
    Mayer EL; Gropper AB; Harris L; Gold JM; Parker L; Kuter I; Come S; Najita JS; Guo H; Winer EP; Burstein HJ
    Clin Breast Cancer; 2015 Feb; 15(1):24-30. PubMed ID: 25205424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
    Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
    Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation, prevention and management of cancer therapy-induced cardiotoxicity: a contemporary approach for clinicians.
    Johnson CB; Sulpher J; Stadnick E
    Curr Opin Cardiol; 2015 Mar; 30(2):197-204. PubMed ID: 25574894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.
    Farolfi A; Melegari E; Aquilina M; Scarpi E; Ibrahim T; Maltoni R; Sarti S; Cecconetto L; Pietri E; Ferrario C; Fedeli A; Faedi M; Nanni O; Frassineti GL; Amadori D; Rocca A
    Heart; 2013 May; 99(9):634-9. PubMed ID: 23349345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.